Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IVA
stocks logo

IVA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast IVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVA is 17.86 USD with a low forecast of 11.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast IVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVA is 17.86 USD with a low forecast of 11.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.180
sliders
Low
11.00
Averages
17.86
High
26.00
Current: 4.180
sliders
Low
11.00
Averages
17.86
High
26.00
Guggenheim
Etzer Darout
Buy
downgrade
$13 -> $11
2025-11-18
Reason
Guggenheim
Etzer Darout
Price Target
$13 -> $11
2025-11-18
downgrade
Buy
Reason
Guggenheim analyst Etzer Darout lowered the firm's price target on Inventiva to $11 from $13 and keeps a Buy rating on the shares after updating the firm's model to incorporate the announcement of $172.5M in equity financing, which the company plans to use to fund continuation of the NATiV3 Phase 3 trial, initiate the outcome trial, and for commercialization activities.
Wolfe Research
Outperform
initiated
$13
2025-11-05
Reason
Wolfe Research
Price Target
$13
2025-11-05
initiated
Outperform
Reason
Wolfe Research initiated coverage of Inventiva with an Outperform rating and $13 price target.
Wolfe Research
Outperform
initiated
$13
2025-11-05
Reason
Wolfe Research
Price Target
$13
2025-11-05
initiated
Outperform
Reason
As previously reported, Wolfe Research initiated coverage of Inventiva with an Outperform rating and $13 price target, calling the Phase 3 NATiV3 topline readout "the single most important event for the company" expected in the second half of 2026 and telling investors that the firm is "constructive" heading into the data. The firm's analysis suggests lanifibranor could demonstrate superior fibrosis improvement efficacy over approved MASH therapies, the analyst noted.
H.C. Wainwright
Ananda Ghosh
initiated
$20
2025-09-03
Reason
H.C. Wainwright
Ananda Ghosh
Price Target
$20
2025-09-03
initiated
Reason
H.C. Wainwright analyst Ananda Ghosh assumed coverage of Inventiva with a Buy rating and $20 price target. The FDA's recent acceptance of the company's letter of intent for liver stiffness measurement as a surrogate endpoint adds positive regulatory momentum for Inventiva, the analyst tells investors in a research note.
Guggenheim
Buy
upgrade
$9 -> $13
2025-09-02
Reason
Guggenheim
Price Target
$9 -> $13
2025-09-02
upgrade
Buy
Reason
Guggenheim raised the firm's price target on Inventiva to $13 from $9 and keeps a Buy rating on the shares. The firm has updated its estimates based on "increased enthusiasm" for the Metabolic-Associated Steatohepatitis market and at-launch target patient population, the analyst tells investors.
Piper Sandler
Overweight
initiated
$26
2025-08-27
Reason
Piper Sandler
Price Target
$26
2025-08-27
initiated
Overweight
Reason
Piper Sandler initiated coverage of Inventiva with an Overweight rating and $26 price target. The company is developing its lead asset, lanifibranor, in metabolic dysfunction-associated steatohepatitis with a Phase 3 readout in the second half of 2026, the analyst tells investors in a research note. The firm sees a buying opportunity at current share levels, saying Inventiva has an oral asset that is "de-risked" for probability of success.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Inventiva SA (IVA.O) is -2.34, compared to its 5-year average forward P/E of -5.04. For a more detailed relative valuation and DCF analysis to assess Inventiva SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.04
Current PE
-2.34
Overvalued PE
0.74
Undervalued PE
-10.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.07
Current EV/EBITDA
-4.38
Overvalued EV/EBITDA
0.76
Undervalued EV/EBITDA
-10.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
46.90
Current PS
65.74
Overvalued PS
87.12
Undervalued PS
6.68
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 681.82% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

IVA News & Events

Events Timeline

(ET)
2025-11-13
09:31:35
Inventiva Prices 32.47M Share Spot Secondary at $3.85
select
2025-11-12 (ET)
2025-11-12
16:46:09
Inventiva Announces Offering of $125M in American Depositary Shares
select
2025-07-09 (ET)
2025-07-09
16:37:31
Inventiva CMO Michael Cooreman to depart, Jason Campagna to succeed
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-28Benzinga
Tilray Brands, SuperX AI Technology, and Other Major Stocks Decline in Friday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by approximately 50 points on Friday.

  • Tilray Brands Inc: Shares of Tilray Brands Inc fell 15% in pre-market trading after announcing a one-for-10 reverse stock split, set to take effect on December 1.

  • Other Stocks Declining: Several other stocks also experienced declines in pre-market trading, including Inventiva ADR (-7.4%), Anglogold Ashanti PLC (-5.5%), and Lexicon Pharmaceuticals Inc (-5%).

  • Market Movements: SuperX AI Technology Ltd saw a significant drop of 3.9% after a previous surge, while Gold Fields Ltd and Abacus Global Management Inc also reported declines following recent gains.

[object Object]
Preview
2.0
11-28Benzinga
Heartbeam Shares Surge Approximately 43%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Heartbeam Inc's Stock Surge: Heartbeam Inc's shares rose 43.3% in pre-market trading after announcing its regulatory strategy following the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software, with plans for an appeal or 510(k) resubmission.

  • Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including SMX PLC (+73.1%), Zenta Group (+26.7%), and Waton Financial (+21.1%), reflecting a positive trend in the market.

  • Major Losers: FBS Global Ltd experienced a sharp decline of 24.3%, while Tilray Brands fell 15% after announcing a reverse stock split, indicating volatility among certain stocks.

  • Market Overview: The pre-market trading session showed mixed results, with notable gains for some companies and significant losses for others, highlighting the fluctuating nature of the stock market.

[object Object]
Preview
9.0
11-28Globenewswire
Inventiva's Shareholders' Meeting Approves All Resolutions Except for the 5th One
  • Shareholder Meeting Outcome: During the shareholders' meeting on November 27, 2025, all resolutions were approved except for the 5th, indicating strong shareholder support for the company's governance and future strategic direction.
  • Voting Participation: A total of 441 shareholders participated, representing 56.432% of the voting rights, highlighting shareholder engagement and enhancing the company's transparency in the capital market.
  • 5th Resolution Rejected: The 5th resolution was rejected with only 41.642% support, reflecting shareholders' cautious stance towards the board's proposal, which may impact the company's future capital structure and employee incentive plans.
  • CEO Compensation Policy Approved: The shareholders unanimously approved the CEO's compensation policy, demonstrating trust in management, which could help attract and retain key talent to drive the company's growth.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Inventiva SA (IVA) stock price today?

The current price of IVA is 4.18 USD — it has increased 0.97 % in the last trading day.

arrow icon

What is Inventiva SA (IVA)'s business?

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

arrow icon

What is the price predicton of IVA Stock?

Wall Street analysts forecast IVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVA is 17.86 USD with a low forecast of 11.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Inventiva SA (IVA)'s revenue for the last quarter?

Inventiva SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Inventiva SA (IVA)'s earnings per share (EPS) for the last quarter?

Inventiva SA. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Inventiva SA (IVA)'s fundamentals?

The market is revising Downward the revenue expectations for Inventiva S.A. (IVA) for FY2025, with the revenue forecasts being adjusted by -0.8% over the past three months. During the same period, the stock price has changed by -24.96%.
arrow icon

How many employees does Inventiva SA (IVA). have?

Inventiva SA (IVA) has 123 emplpoyees as of December 05 2025.

arrow icon

What is Inventiva SA (IVA) market cap?

Today IVA has the market capitalization of 798.46M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free